Kornimate/medical-research-clean huggingface dataset:
prognostic biomarkers in patients with endometrial cancer

Conditions: Endometrial Adenocarcinoma; Recurrent Uterine Corpus Carcinoma; Stage I Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage III Uterine Corpus Cancer; Stage IV Uterine Corpus Cancer

Summary: this research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer.

primary objectives: i. to validate the clinicopathologic associations and prognostic significance of atr mutation in endometrioid endometrial cancer cases with defective dna mismatch repair. outline: this is a multicenter study. dna extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of atr mutation.

Eligibility criteria:
inclusion criteria: * women who were eligible and evaluable for the gog-0210 molecular staging protocol in women with endometrial cancer * women who were registered during the unrestricted enrollment period (through 9/23/07) will automatically qualify * women who were registered during the restricted enrollment period (after 9/23/07) will only be considered if needed * women who had histologically confirmed endometrioid endometrial adenocarcinoma regardless of stage or grade * women who have defective dna mismatch repair and are microsatellite instability positive (msi+ and msi-low) * women who consented to allow their specimens and clinical data to be used for future cancer research * women who have sufficient high-quality genomic dna from tumor available for mutation analysis of atr
postoperative radiotherapy of non-small cell lung cancer: accelerated vs. conventional fractionation

Conditions: Non-Small Cell Lung Cancer

Summary: in this randomized multicentric phase ii study it will be investigated whether an accelerated postoperative radiotherapy with photons or protons (7 fractions per week, 2 gy single dose) may improve locoregional tumour control in non-small cell lung cancer (nsclc) in comparison to conventional fractionation (5 fractions per week, 2 gy single dose).

this study is a randomized multicentric trial. within this study an accelerated irradiation schedule (7 fractions per week, 2 gy single dose) will be compared with the currently used conventional fractionation schedule (5 fractions per week, 2 gy single dose) for postoperative radiotherapy with photons or protons in patients with nsclc. the primary endpoint is locoregional tumour control after 36 months. secondary endpoints are overall survival of patients, local recurrence-free and distant metastases-free survival after 36 months, acute and late toxicity as well as quality of life for both treatment methods.

Eligibility criteria:
inclusion criteria: * histologically confirmed non-small cell lung cancer * previous tumor resection with curative intention * postoperative indication for irradiation (\> pn1 and/ or r1) * r2-resection or recurrence postoperative/after adjuvant chemotherapy diagnosed by the restaging-imaging * exclusion of distant metastases (m0) * age \> 18 years * good general condition (ecog performance status 0 or 1) * written informed consent * appropriate compliance to ensure close follow-up * women of childbearing age: adequate contraception exclusion criteria: * histologically confirmed small cell lung cancer * distant metastases * no written informed consent or lack of cooperation relating to therapy or follow-up * previous (\< 5 years) or concomitant other malignant disease (exception: malignant disease, which is very likely healed and not influenced therapy or follow up of the non-small cell lung cancer, e.g. carcinoma in-situ, basaliomas, very early skin cancers) * for proton therapy: heart pacemaker * previous radiotherapy of the thorax or lower neck region * pregnancy or lactation * participation in another intervention study or not completed follow-up of a intervention study. exceptions are psychological studies, supportive or observation studies, the previous therapy of non-small cell lung cancer is in accordance with the guideline and the participation in radiotherapy studies is not excluded in the trial protocol of the previous study

Keywords: non-small cell lung cancer radiotherapy accelerated fractionation conventional fractionation postoperative
acute diverticulitis and c-reactive protein as a prognostic marker

Conditions: Acute Diverticulitis

Summary: the management of acute diverticulitis maybe better if we have prognostic markers of evolution. hypothesis: c-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis. the investigators need to know the values of c-reactive protein to predict evolution of acute diverticulitis.

a prospective observational study. all the patients with tc-diagnosis of acute diverticulitis (ad) had a c-reactive protein (pcr) in the initial blood test. the investigators will predict evolution of ad with the pcr initial.

Eligibility criteria:
inclusion criteria: * acute diverticulitis exclusion criteria: * other abdominal pathologies
a clinimetric test of spinal sensors in measuring spinal mobility in axial spondyloarthritis

Conditions: Ankylosing Spondylitis; Axial Spondyloarthritis

Summary: this is a clinimetric study to validate the use of imu spinal sensors to measure the range of spinal movement in a group of patients with axial spondyloarthritis.

one of the most important goals of therapy in axial spondyloarthritis is to improve and/or preserve spinal mobility. in the early stages of the disease, spinal stiffness is reversible but eventually the spine can fuse causing permanent loss of flexion. traditional tests for spinal mobility using tape measures are inaccurate and do not capture many aspects of kinematics such as spinal rotation or speed of movement. there is also a need for wearable sensors to give patients feedback and encourage more regular exercise. the investigators will be using imu spinal sensors to measure spinal rom in a group of 40 patients with axial spondyloarthritis. the investigators will be testing aspects of inter-rater and intra-rater reliability, comparing sensor reliability to the accuracy of the traditional tape measure test (basmi).

Eligibility criteria:
inclusion criteria: -confirmed diagnosis of axspa according to the asas criteria exclusion criteria: * severe joint or spinal pain at the time of the study * severely restricted hip movement * history of previous vertebral fracture * history of previous spinal surgery * major scoliosis deformity * pregnancy
promoting adherence to treatment in schizophrenia

Conditions: Schizophrenia

Summary: the project evaluates a culturally adapted, family-based intervention designed to promote treatment adherence among mexican-americans with schizophrenia using a randomized, controlled design in a public mental health setting. mexican-american patients with schizophrenia and their families were randomly assigned to either: 1) one year of multi- family groups that emphasize the importance of attitudes towards adherence, subjective norms, and self-perceived and actual adherence skills in maintaining adherence, added to ongoing customary outpatient care; 2) standard multi-family groups without an emphasis on medication adherence, added to customary outpatient care; or 3) customary outpatient care only (monthly pharmacotherapy sessions and additional services as clinically needed). the study hypotheses are that subjects assigned to the adapted multi-family group would have better medication adherence, less psychiatric symptoms and fewer psychiatric hospitalizations throughout the course of the study (one year of treatment and one year of follow up) compared to the comparison conditions.

as above

Eligibility criteria:
inclusion criteria: * dsm-iv diagnosis of schizophrenia or schizoaffective disorder; * between 18 and 50 years of age; * of mexican origin and speaks spanish fluently; * was without antipsychotic medication without medical authorization for one continuous week in the month prior to hospitalization; * was living with his/her family of origin immediately preceding the inpatient stay and would return to live with his/her family after discharge; and * the patient and at least one family member were willing to participate. exclusion criteria: * patient on conservatorship or legal guardian status

Keywords: medication adherence schizophrenia mexican american multifamily groups
induction immunochemotherapy in stage iii-iva head and neck cancer

Conditions: Neck Cancer

Summary: patients with locally advanced cancer of oropharynx, hypopharynx or larynx and cps\>1 will recieve 3 cycles of induction immunochemotherapy with platinum, 5-fu and pembrolizumab followed by (chemo)radiation.

patients with locally advanced cancer of oropharynx, hypopharynx or larynx and cps\>1 will recieve 3 cycles of induction immunochemotherapy with platinum (cisplatin 75 mg\\m2, 5-fu 1000 mg/m2/day 96-hour infusion and pembrolizumab 200 mg) followed by (chemo)radiation. effect of induction therapy will be assesed by pet/ct and by endoscopic evaluation with biopsy of suspected residual tumor. managemant of any residual tumor will be performed according with local rules and standards.

Eligibility criteria:
inclusion criteria: * squamous cell cancer of oropharynx (p16+: t0-3n3, t4n0-3, p16- : t3-4an0-1, t1-4an2-3), hypopharynx (t2-3n0-3, t1n+, t4an0-3) or larynx iii-iva (t1-2n2-3, t3n2-3, t4an0-3) , tnm8 staging classification; * tumor is morphlogically confirmed; * cps\>1 (22c3 clone); * ecog 0-2; * age above 18 years; * signed informed consent form. exclusion criteria: * cancer of nasopharynx; * non-squamous cell carcimomas or absense of morphological confirmation of squamous cell cancer; * stages i or ii; * ecog\>=3.
use of indocyanine green angiography in critical limb ischemia

Conditions: Peripheral Arterial Disease

Summary: investigators conduct a monocentric pilot study with the objective to determine the hemodynamic parameter of fluorescence angiography (slope, amplitude, saturation time ) best correlated with toe pressure in patients with suspicion of critical limb ischemia.

critical limb ischemia, defined as the presence of chronic ischemic rest pain, ulcers or gangrene attributable to objectively proven arterial occlusive disease, is associated with the appalling prospect that approximately 30% will lose their leg and 25% will die at one year. despite the progress of therapeutics these statistics haven't changed. critical limb ischemia is a clinical diagnosis but should be supported by objective tests. none of theses tests (toe blood pressure (tbp), transcutaneous oxygen pressure (tcpo2) and skin perfusion pressure (spp)) have proven to be enough specific or sensitive, more so they are time consuming, can be subject to several artifacts and may be in some cases discordant making diagnosis difficult. fluorescence angiography has long been used in ophthalmology for the evaluation of the microcirculation of the retina. infracyanine remains within the intravascular space allowing the visualization of the vasculature to a depth of 10 mm. with the fluobeam system, images to a maximal width of 20 cm can be obtained therefore allowing the evaluation of the tissue perfusion of the entire foot. method: fluorescence angiography is performed in the laboratory in the same time as tcpo2, tp and spp. infracyanine is injected in an antecubital vein and visualization and signal acquisition carried out using a specific camera device (fluoptic sas, france) producing the time course of hemodynamic parameters (slope, amplitude, saturation time). 30patients will be evaluated with correlation between data obtained by fluorescence angiography and too blood pressure

Eligibility criteria:
inclusion criteria: * patients with peripheral artery disease and suspicion of critical limb ischemia exclusion criteria: * pregnant women

Keywords: indocyanine angiography ischemia
association between brain stimulations for the rehabilitation of chronic stroke patients

Conditions: Stroke

Summary: cerebrovascular accident (cva) is a cerebrovascular disease with high incidence and morbidity in the brazilian population, and is considered a major cause of disability in adults. brain damage caused by stroke generates a maladaptive pattern of neural activity and modulation between the cerebral hemispheres, unbalancing in the inter-hemispheric inhibition. this condition affects patient's functional recovery. the aim of this study is to verify the effectiveness of repetitive transcranial magnetic stimulation association (rtms) in the cortex motor contralesional, transcranial direct current stimulation (tdcs) in the motor cortex ipsilesional and the association between these two types of brain stimulations on the upper limb recovery after stroke.


Eligibility criteria:
inclusion criteria: * subcortical stroke diagnosis, which has resulted in hemiparesis for at least 6 months and not more than 5 years (chronic condition); * ability to reach 60 degrees in the shoulder flexion * ability to completely extend the fingers in the affected upper limb; * minimal cognitive ability to understand commands; * no current use of antiepileptic drugs for seizures. exclusion criteria: * painful shoulder, adhesive capsulitis or glenohumeral subluxation; * contraindication (presence of metallic implants) or risks for the transcranial magnetic stimulation, as evaluated by means of a standard questionnaire;
prediction of early pre-eclampsia from maternal factors, biophysical and biochemical markers at first trimester

Conditions: Pre-Eclampsia

Summary: the aims of this study are to develop algorithms based on a combination of maternal factors, uterine artery pi, map and serum biomarkers to estimate patient-specific risks for early preeclampsia (pe) and to evaluate the screening performance of such algorithms in twins.

preeclampsia (pe) is still a leading cause of fetal and maternal morbidity and mortality with an incidence of 3-5% worldwide. despite intensive research efforts the pathogenesis of the disease is still unknown but it is likely to be multifactorial.clinical risk factors traditionally have been used to identify women at high risk of developing preeclampsia,and biophysical factors that may help predict hypertensive disorders of pregnancy.in addition,changes in the serum concentrations of angiogenic and antiangiogenic factors are implied in the pathogenesis of pe and have possible relevance in the diagnosis of the disease.

Eligibility criteria:
inclusion criteria: * twins pregnancies delivering a phenotypically normal stillbirth or live birth at or after 24 weeks of gestation. * twins pregnancies at at 11-14 weeks of gestation exclusion criteria: * pregnancies with major fetal abnormalities and those ending in termination, miscarriage or fetal death before 24 weeks
nursing home pain management algorithm clinical trial

Conditions: Pain

Summary: pain assessment and management deficiencies in nursing homes (nhs) are well documented. unrelieved pain in this setting results in poorer resident outcomes, including depression, decreased mobility, sleep disturbance, and impaired physical and social functioning. this randomized controlled trial will evaluate the efficacy of a pain management algorithm coupled with intense diffusion strategies in improving pain, physical function and depression among nh residents. specific aims of the study are to: 1) evaluate the effectiveness of a pain management algorithm (alg) coupled with intense diffusion strategies, as compared with pain education (edu) and weak diffusion strategies, in improving pain, mobility, and depression among nh residents; 2) determine the extent to which adherence to the alg and organizational factors are associated with changes in resident outcomes and the extent to which changes in these variables are associated with changes in outcomes; 3) evaluate the persistence of changes in process and outcome variables at long-term follow-up and 4) evaluate the relationships among behavioral problems and pain in severely cognitively impaired residents who are unable to provide self-report.

inadequate pain management in nursing homes (nhs) is well documented. unrelieved pain in this setting results in depression, decreased mobility, sleep disturbance, and impaired physical and social functioning. this randomized controlled trial will evaluate the efficacy of a pain management algorithm delivered using intense diffusion strategies. outcomes are facility pain practices and residents' pain, physical function and depression. specific aims of the study are to: 1) evaluate the effectiveness of a pain management algorithm (alg) coupled with intense diffusion strategies, as compared with pain education (edu) and weak diffusion strategies, in improving pain, mobility, and depression among nh residents; 2) determine the extent to which adherence to the alg and organizational factors are associated with changes in resident outcomes and the extent to which changes in these variables are associated with changes in outcomes; 3) evaluate the persistence of changes in process and outcome variables at long-term follow-up and 4) evaluate the relationships among behavioral problems and pain in severely cognitively impaired residents who are unable to provide self-report.

Eligibility criteria:
inclusion criteria: * long-term nursing home residents, * 65 years and older, * with moderate or greater pain in the week prior to screening, * residing in a participating facility, * who consent to participate (or whose surrogate decisionmaker consents to participation) exclusion criteria: * short-term stay patients, * persons less than 65 years, * residents on hospice

Keywords: pain depression nursing homes diffusion of innovations clinical trial
study of syb c-1101 in patients with myelodysplastic syndrome

Conditions: Myelodysplastic Syndrome

Summary: to assess tolerability of syb c-1101 when administered orally bid for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (rd). to assess safety, efficacy and pharmacokinetics.


Eligibility criteria:
patients who meet all of the following criteria are eligible for enrollment in the study: 1. histologically or cytologically diagnosed as myelodysplastic syndrome (mds) according to who criteria or fab classification. for patients with raeb in transformation (raeb-t), peripheral wbc is ≦25,000 /mm3 and the disease is stable for at least 4 weeks. 2. classified as intermediate-1, intermediate-2 or high-risk, according to ipss classification. 3. patients with a history of previous treatment of the target disease (e.g., immunosuppressive therapy, protein anabolic steroids, and chemotherapy including azacitidine and lenalidomide) and meet one of the followings: * patients who failed to achieve complete remission, partial remission, or hematologic improvement\* * patients experienced with recurrence/relapse after achieving complete remission, partial remission, or hematologic improvement\* * patients who were intolerable to the previous therapy \*: the most recent assessment of the therapeutic effect based on "clinical application and proposal for modification of the international working group (iwg) response criteria in myelodysplasia" (iwg2006 criteria) 4. off all other treatment (including erythropoiesis stimulating agents) for mds, for at least 4 weeks prior to enrollment and no carry-over (of antitumor effect) from previous treatment is expected as judged by investigator. transfusion is allowed, as clinically indicated. 5. patients with expected survival of ≥3 months. 6. patients aged 20 years or older (at the time of informed consent). 7. ecog performance status (ps) of 0, 1 or 2 8. patients with adequate major organ functions (including the heart, lungs, liver, and kidneys). * ast (got): ≤2.5 -fold the upper limit of normal range at each institution * alt (gpt) : ≤2.5 -fold the upper limit of normal range at each institution * total bilirubin: \<2.0 mg/dl (except patients with gilbert's disease or hemolysis) * serum creatinine: \<2.0 mg/dl * ecg: absence of abnormal findings that require treatment * echocardiography: absence of abnormal findings that require treatment 9. the patient must sign an informed consent form indicating that s/he understands the purpose of and procedure required for the study and is willing to participate in the study.
assessing the effectiveness and safety of pericapsular nerve group (peng) block in hip fracture patients on antithrombotic therapy

Conditions: Hip Fracture; Antithrombotic Therapy; PENG Block

Summary: peng block will be done on patients with hip fracture either receiving antithrombotic therapy or not under ultrasound guidance

patients will be randomized into two groups: group a (antithrombotic therapy group): 50 patients on continuous antithrombotic therapy will receive beng block. group c (control group): 50 patients without antithrombotic therapy will receive beng block. intervention: peng block: standardized administration of the peng block will be performed by experienced anesthesiologists for both groups using ultrasound device. the patients will be subjected to standard monitoring and received nasal cannula oxygen (2 l/min). midazolam (1-2 mg) will be administered intravenously for light sedation. under sterile conditions, a low-frequency curvilinear probe of ultrasound (sonosite s-nerve machine, fujifilm) is initially placed in a transverse plane over the anterior inferior iliac spine, and is then rotated parallel to the pubic ramus to obtain a short-axis view of the iliopsoas muscle and tendon lying on the ramus pubic adjacent to the iliopubic eminence. after skin infiltration with 1-3 ml 1% lidocaine, a 23 g, 70 mm insulated block needle is inserted in-plane in a lateral-to- medial direction to place the tip in the musculofascial plane between the psoas tendon and the pubic ramus. a total of 20 ml 0.5% bupivacaine (astrazeneca, egypt) is injected slowly in 5 ml increments with intermittent aspiration and under constant ultrasound surveillance for adequate fluid spread. thirty minutes after the block completion, standardized endotracheal general anesthesia is induced with propofol (2-2.5 mg/kg), fentanyl (0.5-1,5 μg/kg), and atracurium (0.5 mg/kg).maintenance of anesthesia is done with sevoflurane (2-2.5%) with o2and air 60:40% antithrombotic management: clear protocols for managing antithrombotic therapy in group a will be implemented, considering perioperative bleeding risk

Eligibility criteria:
inclusion criteria: * age 65 years or older * diagnosis of hip fracture * scheduled for surgical intervention within 48 hours * informed consent obtained. exclusion criteria: * allergy to local anesthetics, * contraindications to the peng block * inability to provide informed consent.

Keywords: antithrombotic therapy peng block